Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 3/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | FABP4 | P15090 | 4/20 | 0.37 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.37 |
| ▸ | FABP3 | P05413 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4518934 | 0.93 | MAPT (0.42) | MAPTSMN1; SMN2DHFRPPARGFABP4 | |
| SCHEMBL4496158 | 0.91 | KMT2A (0.40) | MAPTSMN1; SMN2PPARGALDH1A1HTT | |
| SCHEMBL4509036 | 0.91 | MAPT (0.41) | MAPTSMN1; SMN2PPARGALDH1A1HTT | |
| SCHEMBL4500629 | 0.91 | MAPT (0.41) | MAPTSMN1; SMN2PPARGALDH1A1HTT | |
| SCHEMBL1573190 | 0.90 | MAPT (0.39) | MAPTSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL1573417 | 0.89 | KMT2A (0.39) | MAPTSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL4507292 | 0.84 | MAPT (0.44) | MAPTSMN1; SMN2PPARGALDH1A1HTT | |
| SCHEMBL4503963 | 0.82 | MAPT (0.38) | MAPTSMN1; SMN2PPARGALDH1A1HTT | |
| SCHEMBL1573286 | 0.82 | MAPT (0.43) | MAPTALDH1A1HTT | |
| SCHEMBL4506222 | 0.82 | MAPT (0.43) | MAPTALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120819-B2 | FGF-receptor agonist dimeric compounds | SANOFI (FR) | 2015-09-01 | — | — | US | disclosed |
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | FGF2, FGFR1, FGF1 | MAPT 3588/4885SMN1; SMN2 3124/4885DHFR 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.